Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 Aug;56(8):1880–1889. doi: 10.1128/iai.56.8.1880-1889.1988

Virulence properties and protective efficacy of the capsular polymer of Haemophilus (Actinobacillus) pleuropneumoniae serotype 5.

T J Inzana 1, J Ma 1, T Workman 1, R P Gogolewski 1, P Anderson 1
PMCID: PMC259496  PMID: 3397178

Abstract

The role of the capsule of Haemophilus (Actinobacillus) pleuropneumoniae serotype 5 in bacterial virulence, and the protective efficacy of antibody to serotype 5 capsule was investigated. Encapsulated H. pleuropneumoniae serotype 5 were resistant to killing by complement and antibody to capsule or somatic antigens, whereas a noncapsulated mutant was sensitive to killing by the alternative complement pathway alone. Antiserum to whole H. pleuropneumoniae serotype 5 bacteria or monospecific antiserum to capsule was capable of opsonizing bacteria of the homologous serotype for phagocytosis by swine polymorphonuclear leukocytes but was not opsonic for a heterologous serotype. An immunoglobulin M monoclonal antibody to the serotype 5 capsule was not opsonic for any serotype. Mice were protected against lethal, intranasal challenge with the homologous or heterologous serotype after immunization with live encapsulated or noncapsulated bacteria, but not after immunization with killed bacteria, lipopolysaccharide, or a capsule-protein conjugate vaccine. The protection induced by immunization with live bacteria was transferred to nonimmune, syngeneic mice by serum but not by spleen cells. Nonimmune pigs passively immunized with monospecific swine serum to capsule were protected from lethal infection but not from development of hemorrhagic lung lesions, whereas pigs passively immunized with swine antiserum to live bacteria did not develop severe respiratory lesions. Thus, the capsule of H. pleuropneumoniae serotype 5 was inhibitory to the bactericidal activity of serum and was antiphagocytic. Antibody to the capsule was opsonic but was not fully protective.

Full text

PDF
1880

Images in this article

1884Image
on p.1884

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen P. M., Roberts I., Boulnois G. J., Saunders J. R., Hart C. A. Contribution of capsular polysaccharide and surface properties to virulence of Escherichia coli K1. Infect Immun. 1987 Nov;55(11):2662–2668. doi: 10.1128/iai.55.11.2662-2668.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avery O. T., Macleod C. M., McCarty M. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III. J Exp Med. 1944 Feb 1;79(2):137–158. doi: 10.1084/jem.79.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Branefors P., Dahlberg T. Serum bactericidal effect on capsulated and non-capsulated Haemophilus influenzae. Acta Pathol Microbiol Scand C. 1980 Feb;88(1):47–56. doi: 10.1111/j.1699-0463.1980.tb00071.x. [DOI] [PubMed] [Google Scholar]
  4. Confer A. W., Panciera R. J., Fulton R. W., Gentry M. J., Rummage J. A. Effect of vaccination with live or killed Pasteurella haemolytica on resistance to experimental bovine pneumonic pasteurellosis. Am J Vet Res. 1985 Feb;46(2):342–347. [PubMed] [Google Scholar]
  5. Fenwick B. W., Cullor J. S., Osburn B. I., Olander H. J. Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine. Infect Immun. 1986 Aug;53(2):298–304. doi: 10.1128/iai.53.2.298-304.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fenwick B. W., Osburn B. I. Immune responses to the lipopolysaccharides and capsular polysaccharides of Haemophilus pleuropneumoniae in convalescent and immunized pigs. Infect Immun. 1986 Nov;54(2):575–582. doi: 10.1128/iai.54.2.575-582.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fenwick B. W., Osburn B. I., Olander H. J. Resistance of C3H/HeJ mice to the effects of Haemophilus pleuropneumoniae. Infect Immun. 1986 Sep;53(3):474–479. doi: 10.1128/iai.53.3.474-479.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Higgins R., Larivière S., Mittal K. R., Martineau G. P., Rousseau P., Cameron J. Evaluation of a Killed Vaccine Against Porcine Pleuropneumonia Due to Haemophilus pleuropneumoniae. Can Vet J. 1985 Feb;26(2):86–89. [PMC free article] [PubMed] [Google Scholar]
  9. Horwitz M. A. Phagocytosis of microorganisms. Rev Infect Dis. 1982 Jan-Feb;4(1):104–123. doi: 10.1093/clinids/4.1.104. [DOI] [PubMed] [Google Scholar]
  10. Horwitz M. A., Silverstein S. C. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J Clin Invest. 1980 Jan;65(1):82–94. doi: 10.1172/JCI109663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Inman J. K., Dintzis H. M. The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents. Biochemistry. 1969 Oct;8(10):4074–4082. doi: 10.1021/bi00838a026. [DOI] [PubMed] [Google Scholar]
  12. Inzana T. J., Anderson P. Serum factor-dependent resistance of Haemophilus influenzae type b to antibody to lipopolysaccharide. J Infect Dis. 1985 May;151(5):869–877. doi: 10.1093/infdis/151.5.869. [DOI] [PubMed] [Google Scholar]
  13. Inzana T. J., Mathison B. Serotype specificity and immunogenicity of the capsular polymer of Haemophilus pleuropneumoniae serotype 5. Infect Immun. 1987 Jul;55(7):1580–1587. doi: 10.1128/iai.55.7.1580-1587.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Inzana T. J. Purification and partial characterization of the capsular polymer of Haemophilus pleuropneumoniae serotype 5. Infect Immun. 1987 Jul;55(7):1573–1579. doi: 10.1128/iai.55.7.1573-1579.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Inzana T. J., Tosi M. F., Kaplan S. L., Anderson D. C., Mason E. O., Jr, Williams R. P. Effect of Haemophilus influenzae type b lipopolysaccharide on complement activation and polymorphonuclear leukocyte function. Pediatr Res. 1987 Dec;22(6):659–666. doi: 10.1203/00006450-198712000-00010. [DOI] [PubMed] [Google Scholar]
  16. Kasper D. L. Bacterial capsule--old dogmas and new tricks. J Infect Dis. 1986 Mar;153(3):407–415. doi: 10.1093/infdis/153.3.407. [DOI] [PubMed] [Google Scholar]
  17. LITTLEFIELD J. W. SELECTION OF HYBRIDS FROM MATINGS OF FIBROBLASTS IN VITRO AND THEIR PRESUMED RECOMBINANTS. Science. 1964 Aug 14;145(3633):709–710. doi: 10.1126/science.145.3633.709. [DOI] [PubMed] [Google Scholar]
  18. Martin S. W. Vaccination: Is it Effective in Preventing Respiratory Disease or Influencing Weight Gains in Feedlot Calves? Can Vet J. 1983 Jan;24(1):10–19. [PMC free article] [PubMed] [Google Scholar]
  19. Maudsley J. R., Kadis S. Growth and hemolysin production by Haemophilus pleuropneumoniae cultivated in a chemically defined medium. Can J Microbiol. 1986 Oct;32(10):801–805. doi: 10.1139/m86-147. [DOI] [PubMed] [Google Scholar]
  20. Moxon E. R., Deich R. A., Connelly C. Cloning of chromosomal DNA from Haemophilus influenzae. Its use for studying the expression of type b capsule and virulence. J Clin Invest. 1984 Feb;73(2):298–306. doi: 10.1172/JCI111214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Moxon E. R., Vaughn K. A. The type b capsular polysaccharide as a virulence determinant of Haemophilus influenzae: studies using clinical isolates and laboratory transformants. J Infect Dis. 1981 Apr;143(4):517–524. doi: 10.1093/infdis/143.4.517. [DOI] [PubMed] [Google Scholar]
  22. Newman S. L., Johnston R. B., Jr Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b. J Immunol. 1979 Oct;123(4):1839–1846. [PubMed] [Google Scholar]
  23. Newman S. L., Waldo B., Johnston R. B., Jr Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b. Infect Immun. 1973 Sep;8(3):488–490. doi: 10.1128/iai.8.3.488-490.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nielsen R. Haemophilus parahaemolyticus serotypes. Pathogenicity and cross immunity. Nord Vet Med. 1979 Oct;31(10):407–413. [PubMed] [Google Scholar]
  25. Nielsen R. Haemophilus pleuropneumoniae serotypes--cross protection experiments. Nord Vet Med. 1984 Jul-Aug;36(7-8):221–234. [PubMed] [Google Scholar]
  26. Nielsen R. Pleuropneumonia of swine caused by Haemophilus parahaemolyticus. Studies on the protection obtained by vaccination. Nord Vet Med. 1976 Jul-Aug;28(7-8):337–348. [PubMed] [Google Scholar]
  27. Robbins J. B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry. 1978 Nov;15(10-11):839–854. doi: 10.1016/0161-5890(78)90117-7. [DOI] [PubMed] [Google Scholar]
  28. Rosendal S., Miniats O. P., Sinclair P. Protective efficacy of capsule extracts of Haemophilus pleuropneumoniae in pigs and mice. Vet Microbiol. 1986 Sep;12(3):229–240. doi: 10.1016/0378-1135(86)90052-0. [DOI] [PubMed] [Google Scholar]
  29. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schreiber J. R., Barrus V., Cates K. L., Siber G. R. Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of Haemophilus influenzae type b. J Infect Dis. 1986 Jan;153(1):8–16. doi: 10.1093/infdis/153.1.8. [DOI] [PubMed] [Google Scholar]
  31. Sebunya T. N., Saunders J. R. Haemophilus pleuropneumoniae infection in swine: a review. J Am Vet Med Assoc. 1983 Jun 15;182(12):1331–1337. [PubMed] [Google Scholar]
  32. Sebunya T. N., Saunders J. R. Studies on immunity to Haemophilus pleuropneumoniae infections in mice. Am J Vet Res. 1982 Oct;43(10):1793–1798. [PubMed] [Google Scholar]
  33. Taylor P. W. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev. 1983 Mar;47(1):46–83. doi: 10.1128/mr.47.1.46-83.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tosi M. F., Kaplan S. L., Mason E. O., Buffone G. J., Anderson D. C. Generation of chemotactic activity in serum by Haemophilus influenzae type b. Infect Immun. 1984 Feb;43(2):593–599. doi: 10.1128/iai.43.2.593-599.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Warren H. S., Novitsky T. J., Bucklin A., Kania S. A., Siber G. R. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria. Infect Immun. 1987 Jul;55(7):1668–1673. doi: 10.1128/iai.55.7.1668-1673.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Weller P. F., Smith A. L., Smith D. H., Anderson P. Role of immunity in the clearance of bacteremia due to Haemophilus influenzae. J Infect Dis. 1978 Oct;138(4):427–436. doi: 10.1093/infdis/138.4.427. [DOI] [PubMed] [Google Scholar]
  37. Woodward T. E., Woodward W. E. A new oral vaccine against typhoid fever. J Infect Dis. 1982 Mar;145(3):289–291. doi: 10.1093/infdis/145.3.289. [DOI] [PubMed] [Google Scholar]
  38. Zwahlen A., Winkelstein J. A., Moxon E. R. Surface determinants of Haemophilus influenzae pathogenicity: comparative virulence of capsular transformants in normal and complement-depleted rats. J Infect Dis. 1983 Sep;148(3):385–394. doi: 10.1093/infdis/148.3.385. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES